The Effect of NB-UVB on Interleukin-36 Levels in Psoriasis

Cairo University (CU) logo

Cairo University (CU)

Status

Unknown

Conditions

Psoriasis

Treatments

Device: NB-UVB

Study type

Interventional

Funder types

Other

Identifiers

NCT03526705
Kapu1

Details and patient eligibility

About

Psoriasis is an immune-mediated skin disease that affects 1-2 % of the population. Several cytokines have been found to be involved in the complex pathogenesis of this disease. Il- 36 is one of the cytokines sharing in psoriasis pathogenesis, as its levels are elevated in psoriatic plaques. Cathepsin G is known to activate Il- 36 and promote inflammation in psoriasis.NB-UVB is one of the important treatment modalities for psoriasis. The aim of this study is to detect the effect of NB-UVB on the lesional levels of IL-36 in psoriasis.

Full description

25 psoriasis patients will receive 26 sessions of phototherapy (NB-UVB). Patients will receive 3 sessions per week. Tissue levels of IL-36 and Cathepsin G will be assessed in skin lesions before starting treatment and after completing the 26 sessions.

Enrollment

25 estimated patients

Sex

All

Ages

18 to 60 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Patients with psoriasis vulgaris of both sexes
  • Age between 18 and 60 years old.

Exclusion criteria

  • Pregnant females
  • Patients receiving systemic treatment or topical treatment for psoriasis within the past two months.
  • Patients having other dermatological diseases.

Trial design

Primary purpose

Other

Allocation

N/A

Interventional model

Single Group Assignment

Masking

None (Open label)

25 participants in 1 patient group

nb-uvb
Experimental group
Description:
psoriasis patients will receive 26 sessions of nb-uvb phototherapy
Treatment:
Device: NB-UVB

Trial contacts and locations

0

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems